In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Amicus buys Celenex for up to $452mm, acquiring ten rare disease pipeline programs

Executive Summary

Supporting its business strategy to move into the gene therapy arena, Amicus Therapeutics Inc. agreed to acquire privately held Celenex (gene therapies for neurological lysosomal storage disorders (LSDs)), gaining ten rare disease pipeline projects.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register